Cytodigm

Cytodigm is a private, preclinical-stage biopharmaceutical company focused on targeted drug delivery for genetic medicine, gene therapy, immune therapy, and other in vivo therapeutics. The company is building a portfolio of proprietary nanoparticle delivery platforms designed to improve tissue targeting beyond the liver, reduce immunogenicity, and enable redosing. Its lead technology brands include Cytofinity for PEG-free lipid nanoparticles, Sigfinity for lung-tropic lipoplex delivery of nucleic acids, and Zetafinity for polymer nanoparticles that deliver small molecules, peptides, and proteins to immune cells. Cytodigm also advances internal therapeutic programs, including PPRX-1701 for glioblastoma-related drug delivery, while partnering and out-licensing its delivery technologies to other biopharma companies. The company positions itself as a platform-enabled drug delivery innovator supporting both internal development and external collaborations.